Contact
searchSearch
HMP Global
Login

Cutaneous Squamous Cell Carcinoma Specialty Channel

Cutaneous Squamous Cell Carcinoma
Specialty Channel
News
Identification of a High-Risk Subgroup With Poor Disease-Free Survival After Postoperative Radiotherapy for Cutaneous Squamous Cell Carcinoma
02/04/2026
Stephanie Holland
Secondary analysis results from the phase 3 TROG 05.01 trial identified that patients with cutaneous squamous cell carcinoma of the head and neck who display higher risk features experience significantly worse DFS following postoperative...
Secondary analysis results from the phase 3 TROG 05.01 trial identified that patients with cutaneous squamous cell carcinoma of the head and neck who display higher risk features experience significantly worse DFS following postoperative...
Secondary analysis results from...
02/04/2026
Oncology
Quiz
Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
02/04/2026
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA...
02/04/2026
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
FDA Approval
FDA Approves Cemiplimab for Patients With Cutaneous Squamous Cell Carcinoma in the Adjuvant Setting
10/08/2025
Allison Casey
The US FDA approved cemiplimab for the adjuvant treatment of patients with cutaneous squamous cell carcinoma who are at high risk for recurrence following surgery and radiation.
The US FDA approved cemiplimab for the adjuvant treatment of patients with cutaneous squamous cell carcinoma who are at high risk for recurrence following surgery and radiation.
The US FDA approved cemiplimab...
10/08/2025
Oncology
News
Using Risk Factors for Metastasis to Improve Cutaneous Squamous Cell Carcinoma Staging Systems
08/09/2022
Derek Cowsert
Retrospective study aims to identify variables for significant risk of metastasis in patients with cutaneous squamous cell carcinoma.
Retrospective study aims to identify variables for significant risk of metastasis in patients with cutaneous squamous cell carcinoma.
Retrospective study aims to...
08/09/2022
Oncology

News

News
Identification of a High-Risk Subgroup With Poor Disease-Free Survival After Postoperative Radiotherapy for Cutaneous Squamous Cell Carcinoma
02/04/2026
Stephanie Holland
Secondary analysis results from the phase 3 TROG 05.01 trial identified that patients with cutaneous squamous cell carcinoma of the head and neck who display higher risk features experience significantly worse DFS following postoperative...
Secondary analysis results from the phase 3 TROG 05.01 trial identified that patients with cutaneous squamous cell carcinoma of the head and neck who display higher risk features experience significantly worse DFS following postoperative...
Secondary analysis results from...
02/04/2026
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Using Risk Factors for Metastasis to Improve Cutaneous Squamous Cell Carcinoma Staging Systems
08/09/2022
Derek Cowsert
Retrospective study aims to identify variables for significant risk of metastasis in patients with cutaneous squamous cell carcinoma.
Retrospective study aims to identify variables for significant risk of metastasis in patients with cutaneous squamous cell carcinoma.
Retrospective study aims to...
08/09/2022
Oncology

Interactive Features

Quiz
Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
02/04/2026
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA...
02/04/2026
Oncology

Recent News

News
Identification of a High-Risk Subgroup With Poor Disease-Free Survival After Postoperative Radiotherapy for Cutaneous Squamous Cell Carcinoma
02/04/2026
Stephanie Holland
Secondary analysis results from the phase 3 TROG 05.01 trial identified that patients with cutaneous squamous cell carcinoma of the head and neck who display higher risk features experience significantly worse DFS following postoperative...
Secondary analysis results from the phase 3 TROG 05.01 trial identified that patients with cutaneous squamous cell carcinoma of the head and neck who display higher risk features experience significantly worse DFS following postoperative...
Secondary analysis results from...
02/04/2026
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Using Risk Factors for Metastasis to Improve Cutaneous Squamous Cell Carcinoma Staging Systems
08/09/2022
Derek Cowsert
Retrospective study aims to identify variables for significant risk of metastasis in patients with cutaneous squamous cell carcinoma.
Retrospective study aims to identify variables for significant risk of metastasis in patients with cutaneous squamous cell carcinoma.
Retrospective study aims to...
08/09/2022
Oncology
News
Nivolumab Plus Chemotherapy Maintains Survival Advantage in Gastroesophageal Adenocarcinoma
02/12/2026
Stephanie Holland
Long-term follow-up results from the phase 3 CheckMate 649 trial demonstrate that adding nivolumab to chemotherapy continues to prolong survival in previously untreated patients with non-HER2-positive, unresectable or metastatic...
Long-term follow-up results from the phase 3 CheckMate 649 trial demonstrate that adding nivolumab to chemotherapy continues to prolong survival in previously untreated patients with non-HER2-positive, unresectable or metastatic...
Long-term follow-up results from...
02/12/2026
Oncology
News
Iopofosine I 131 Shows Durable Responses in Heavily Pretreated Waldenström Macroglobulinemia
02/12/2026
Emily Estrada
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug...
02/12/2026
Radiopharmaceutical Education Institute
News
Maintenance Palbociclib Extends PFS in HR-Positive, HER2-Positive Metastatic Breast Cancer
02/11/2026
Stephanie Holland
Results from the phase 3 PATINA trial demonstrated that the adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved progression-free survival in HR-positive, HER2-positive metastatic breast cancer.
Results from the phase 3 PATINA trial demonstrated that the adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved progression-free survival in HR-positive, HER2-positive metastatic breast cancer.
Results from the phase 3 PATINA...
02/11/2026
Oncology
News
First-Line Toripalimab Improves PFS in Advanced Melanoma Predominantly of Acral Subtype
02/11/2026
Stephanie Holland
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3...
02/11/2026
Oncology
FDA Approval
FDA Approves Pembrolizumab-Based Regimens for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
02/10/2026
Emily Estrada
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA...
02/10/2026
Oncology
Conference Coverage
Post-Treatment Plasma ctDNA Accurately Identifies Recurrence in Muscle-Invasive Bladder Cancer
02/09/2026
Stephanie Holland
Key Clinical Takeaways:  Design/Population: This retrospective study evaluated plasma ctDNA in 42 patients with muscle-invasive bladder cancer treated with trimodality therapy. Patients were stratified by post-treatment ctDNA...
Key Clinical Takeaways:  Design/Population: This retrospective study evaluated plasma ctDNA in 42 patients with muscle-invasive bladder cancer treated with trimodality therapy. Patients were stratified by post-treatment ctDNA...
Key Clinical...
02/09/2026
Oncology
Conference Coverage
Selective Use of Stereotactic Ablative Radiotherapy Enables Durable Disease Control in Oligoprogressive Metastatic Renal Cell Carcinoma
02/06/2026
Stephanie Holland
Stereotactic ablative radiotherapy provides durable local control and delays systemic therapy escalation in selected patients with oligoprogressive metastatic renal cell carcinoma receiving systemic therapy.
Stereotactic ablative radiotherapy provides durable local control and delays systemic therapy escalation in selected patients with oligoprogressive metastatic renal cell carcinoma receiving systemic therapy.
Stereotactic ablative...
02/06/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Pimicotinib in Tenosynovial Giant Cell Tumor
02/06/2026
Stephanie Holland
Based on results from the phase 3 MANEUVER trial, the FDA accepted the New Drug Application for pimicotinib for the treatment of patients with tenosynovial giant cell tumor.
Based on results from the phase 3 MANEUVER trial, the FDA accepted the New Drug Application for pimicotinib for the treatment of patients with tenosynovial giant cell tumor.
Based on results from the phase...
02/06/2026
Oncology
News
LDH and α-HBDH as Prognostic Biomarkers in Extensive-Stage Small Cell Lung Cancer
02/06/2026
Emily Estrada
Elevated baseline and early on-treatment serum levels of LDH and α-HBDH following first-line chemoimmunotherapy were independently associated with survival outcomes in extensive-stage small cell lung cancer.
Elevated baseline and early on-treatment serum levels of LDH and α-HBDH following first-line chemoimmunotherapy were independently associated with survival outcomes in extensive-stage small cell lung cancer.
Elevated baseline and early...
02/06/2026
Oncology
News
Zanzalintinib Plus Atezolizumab Significantly Improves OS in Relapsed or Refractory Metastatic Colorectal Cancer
02/06/2026
Stephanie Holland
Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab significantly improves overall survival compared with regorafenib in relapsed or refractory metastatic colorectal cancer without MSI-H or dMMR tumors.
Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab significantly improves overall survival compared with regorafenib in relapsed or refractory metastatic colorectal cancer without MSI-H or dMMR tumors.
Results from the STELLAR-303...
02/06/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use